Dr. Neda Shakour, Mashhad University of Medical Science, Iran
Dr. Neda Shakour is a distinguished medicinal chemist at Mashhad University of Medical Sciences, specializing in drug design for diabetes treatment. With a Ph.D. in Medicinal Chemistry, her research focuses on thiazolidinediones and in silico drug discovery. She has extensive teaching experience and has contributed to regulatory work at the Food and Drug Administration of Mashhad. Recognized with numerous awards and research grants, Dr. Shakour has published extensively on cancer therapies, metabolic diseases, and nanomedicine, making significant advancements in medical science. ππ¬
Publication Profile
Google Scholar
π Education
Dr. Neda Shakour earned her Ph.D. in Medicinal Chemistry from Mashhad University of Medical Sciences, focusing on designing and synthesizing novel thiazolidinediones for diabetes treatment. She completed her M.Sc. in Organic Chemistry at the University of Zanjan, where she specialized in nanoscale compound synthesis. Her academic journey began with a B.Sc. in Chemistry from Islamic Azad University of Shahreza. Throughout her studies, Dr. Shakour demonstrated exceptional research capabilities, gaining recognition for her contributions to medicinal chemistry. ππ§ͺ
π©βπ« Experience
Dr. Neda Shakour has over a decade of teaching experience at institutions like the Non-Profit Institute of the Role of the World in Isfahan, Shahreza University, and Borujen University. From 2021 to 2023, she worked as a postdoctoral researcher at Mashhad University of Medical Sciences, specializing in drug discovery. Currently, she is actively contributing to the Food and Drug Administration of Mashhad, where she applies her expertise in medicinal chemistry to enhance drug regulation and healthcare policies. ππ
π
Awards and Honors
Dr. Neda Shakour was awarded the Level 3 Research and Innovation Credit by the National Elite Foundation in 2010. In 2024-2025, she secured prestigious research grants for two groundbreaking projects on non-peptide GLP-1R natural agonists and kidney failure treatments. Her consistent recognition for research excellence underscores her impact in drug discovery and diabetes management. With her dedication to innovation, Dr. Shakour remains a leader in medicinal chemistry research. π₯π¬
π Research Focus
Dr. Neda Shakour’s research spans the design, synthesis, and biological evaluation of organic compounds, particularly thiazolidinediones for diabetes treatment. She specializes in in silico drug discovery, biomimetic synthesis, and the development of targeted therapies for metabolic diseases. Her work also addresses cancer treatments and fibrosis management, demonstrating a commitment to improving patient outcomes. Dr. Shakourβs research significantly advances therapeutic innovation in pharmaceutical science. π‘π§ͺ
Publication Top Notes
-
π The natural phenolic compounds as modulators of NADPH oxidases in hypertension – Phytomedicine 55, 200-213 – Cited by: 176 – Year: 2019 πΏ
-
π Statins and C-reactive protein: in silico evidence on direct interaction – Archives of Medical Science 16 (6), 1432-1439 – Cited by: 60 – Year: 2020 π
-
π Ethnobotany, Phytochemistry and Pharmacological Features of Centella asiatica: A Comprehensive Review – Pharmacological Properties of Plant-Derived Natural Products – Cited by: 35 – Year: 2021 π±
-
π Docetaxel encapsulation in nanoscale assembly micelles for targeted metastatic breast cancer therapy – International Journal of Pharmaceutics 605, 120822 – Cited by: 31 – Year: 2021 π§¬
-
π In silico evidence of direct interaction between statins and Ξ²βamyloid – Journal of Cellular Biochemistry 120 (3), 4710-4715 – Cited by: 23 – Year: 2019 π§
-
π Cellulose-based nanofibril composite materials for bacterial infection control – Frontiers in Bioengineering and Biotechnology 9, 732461 – Cited by: 22 – Year: 2021 π¦
-
π Design, synthesis and biological evaluation of novel thiazolidinediones as antidiabetic agents – Bioorganic Chemistry 115, 105162 – Cited by: 20 – Year: 2021 π
-
π Data mining approaches to explore the association between type 2 diabetes mellitus with SARS-CoV-2 – BMC Pulmonary Medicine 23 (1), 1-14 – Cited by: 19 – Year: 2023 π©Έ
-
π Candesartan inhibits tumor growth and fibrosis in colorectal cancer – Excli Journal 20, 863 – Cited by: 17 – Year: 2021 π§ββοΈ
-
π Dual targeting of TGF-Ξ² and PD-L1 in colorectal carcinoma – Life Sciences 328, 121865 – Cited by: 13 – Year: 2023 π§«